Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

L. Maude, Shannon; V. Frey, Noelle; A. Shaw, Pamela; Aplenc, Richard; M. Barrett, David; Bunin, Nancy; Chew, Anne; Gonzalez, Vanessa; Zheng, Zhaohui; F. Lacey, Simon; D. Mahnke, Yolanda; Joseph Melenhorst, J.; R. Rheingold, Susan; Shen, Angela; T. Teachey, David; L. Levine, Bruce; H. June, Carl; L. Porter, David; A. Grupp, Stephan

doi:10.1056/nejmoa1407222

Public

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Published in New England Journal of Medicine • Oct 15, 2014

Authors:

Shannon L. Maude

Noelle V. Frey

Pamela A. Shaw

Abstract

BACKGROUND: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease. ...

Subject

Chimeric antigen receptor

Immunology

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!